Femasys : Shareholder Update – Q1 2026
FEMY
Published on 04/16/2026 at 11:38 am EDT
Dear Shareholder,
STRATEGIC PARTNERSHIPS
Entered a strategic distribution partnership with OR Consulting to support commercial launch of FemBloc®, FemaSeed® and other products within the portfolio in Switzerland.
Established partnership with Refuah Health Center, advancing adoption of FemaSeed® as a first-line infertility treatment in community-based care.
KEY MILESTONES
Initiated patient enrollment in the FINALE pivotal clinical trial evaluating FemBloc®, advancing toward U.S. approval.
FemBloc® permanent birth control system achieved certification under the Medical Device Single Audit Program (MDSAP), supporting global regulatory readiness.
Received AMA CPT Editorial Panel approval of a new Category III CPT code for FemaSeed® intratubal insemination (ITI), supporting future reimbursement pathway.
Appointed Kenneth D. Eichenbaum, M.D., M.S.E., to the Board of Directors, strengthening leadership and strategic oversight.
Appointed John Canning as Chief Operating Officer to drive operational execution and advance commercial growth.
Building on 2025 momentum, Femasys made meaningful progress in Q1 2026-advancing regulatory initiatives, expanding partnerships, accelerating commercialization efforts, and strengthening our leadership team-all in support of increasing access to cost-effective fertility and permanent birth control solutions worldwide.
On behalf of the entire Femasys management team, we appreciate your continued support and confidence. As we move through 2026, we are entering an important phase of U.S. commercialization, with the introduction of FemSperm expected to activate the OB/GYN call point, expand access beyond fertility centers, and unlock the broader potential of our fertility portfolio through earlier intervention in the care pathway. We have also initiated patient enrollment in the FemBloc FINALE trial supporting U.S. approval and look forward to advancing this important product initiative. We look forward to the progress ahead.
Sincerely,
Kathy Lee-Sepsick
Chief Executive Officer and Founder
1
Shareholder Update
Q1 2026 Highlights
Raising Our Profile with Major Market Media
We continue to building awareness of our women's health product platform through expanding coverage in leading national and industry media outlets.
NATIONAL MEDIA COVERAGE
Influencial Women Podcast - April https://influentialwomen.com/podcasts/from-lab-to-life-the-journey-behind-solving-womens-healthcare
NATIONAL INVESTOR MEDIA
American Market News - March https://www.americanbankingnews.com/2026/03/06/femasys-nasdaqfemy-research-coverage-started-at-lake-street-capital.html
GuruFocus - February https://www.gurufocus.com/news/8657362/femy-stock-soars-as-fembloc-birth-control-system-gains-mdsap-certification
Investing.com - February https://www.investing.com/news/stock-market-news/femasys-stock-rises-on-new-distribution-partnership-in-switzerland-93CH-4482530
Seeking Alpha - January https://seekingalpha.com/news/4539113-femasys-secures-nasdaq-extension-to-regain-bid-price-compliance
Coverage initiated by Ben Haynor, LakeStreet in March 2026 with a BUY rating.
Local and regional market testimonials by physicians further substantiate the impact our products are having in the marketplace.
"At Refuah, our focus is on providing patients with practical, evidence-based options that can streamline the fertility journey. FemaSeed offers an accessible, patient-centered approach that may help many individuals begin care sooner and with less complexity, and we are pleased to make it available as an early step in treatment."
ANGELA SILBER, MD
OB/GYN at Refuah Health Center
FemBloc Spotlighted at Spanish Congress with CEO Feature
Spanish Society of Contraception Annual Congress | March 12, 2026
Our partners in Spain, CMQ and Durgalab, represented FemBloc strongly at the Congress of the Spanish Society of Contraception (SEC) in Seville (March 11-13), where the official program featured a dedicated symposium, "FemBloc: Innovation in Permanent Contraception-A Natural, Non-Surgical, Implant-Free Method," presented by Laura San Juan Sáenz on March 12. The session, held within the core scientific program, drew standing-room-only attendance with over 400 participants onsite and more than 600 midwives joining remotely, reflecting significant clinical interest in new approaches to permanent contraception. The program included a video introduction from Femasys CEO Kathy Lee-Sepsick, followed by a physician presentation reviewing the FemBloc product and procedure, the importance of expanding contraceptive options, and the ongoing post-market surveillance study, reinforcing FemBloc's positioning as a differentiated solution in permanent contraception.
KEEP IN TOUCH
As we execute our mission to advance women's reproductive health options in critical areas, we welcome you to stay connected and follow Femasys' progress into 2026 and beyond. To stay up to date on everything Femasys, please visit the Investor Relations section of the Femasys
ir.femasys.com website and sign up for email alerts, or contact us [email protected].
877-336-2562
2
© 2026 Femasys Inc. 05680 R00 10 April 2026
Disclaimer
Femasys Inc. published this content on April 16, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on April 16, 2026 at 15:37 UTC.